Sienna Biopharmaceuticals, Inc.
SNNA
SNNA was delisted on the 16th of December, 2019.
60 hedge funds and large institutions have $21.6M invested in Sienna Biopharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 19 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
11% more funds holding
Funds holding: 54 → 60 (+6)
21% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 19
86% less capital invested
Capital invested by funds: $151M → $21.6M (-$129M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.36M |
| 2 |
Renaissance Technologies
New York
|
+$1.05M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$591K |
| 4 |
Two Sigma Investments
New York
|
+$565K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$450K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$7.55M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.79M |
| 3 |
BlackRock
New York
|
-$2.21M |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$944K |
| 5 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$594K |
SNNA Hedge Fund Activity: Q4 2018 in Review
60 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Sienna Biopharmaceuticals, Inc. (SNNA) for Q4 2018, worth a combined $21.6M — down 86% from $151M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new SNNA positions and 6 closed out — a net gain of 6 holders — while 15 added to existing stakes and 19 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.36M. The largest seller was Victory Capital Management, exiting entirely with an estimated $7.55M sold.
- 60 institutional investors held Sienna Biopharmaceuticals, Inc. (SNNA) as of Q4 2018, up from 54 in Q3 2018.
- Funds reported $21.6M of Sienna Biopharmaceuticals, Inc. stock for Q4 2018, down 86% quarter-over-quarter.
- 12 funds opened new Sienna Biopharmaceuticals, Inc. positions in Q4 2018 and 6 closed out, a net change of +6 holders.
- The largest Sienna Biopharmaceuticals, Inc. buyer in Q4 2018 was Morgan Stanley, an estimated $1.36M added.
- The largest Sienna Biopharmaceuticals, Inc. seller in Q4 2018 was Victory Capital Management, an estimated $7.55M sold.
Based on aggregated 13F filings for Q4 2018.